53 results
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
7 Nov 19
Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update
4:53pm
results
Reported first sustained objective response in patient with Ewing sarcoma treated with TK216 in Phase 1 clinical trial
Strengthened leadership … of these product candidates,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO. “We have now rounded out an experienced leadership team
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
7 Mar 19
Entry into a Material Definitive Agreement
7:33am
, and enable the continued development of our first-in-class SARD technology by a company whose leadership has deep experience in developing oncology … . and will be headquartered in San Diego, California under the leadership of Oncternal’s current management team. Although no GTx employee is expected
425
ONCT
Oncternal Therapeutics Inc
7 Mar 19
Business combination disclosure
5:12pm
and its leadership over the past few months. The entire team has been mission-oriented and fully focused on creating long term value for shareholders. We … Diego, where we’ve built an experienced leadership team. Through multiple financing rounds as a private company, we’ve succeeded in attracting investors
425
EX-99.1
6lwz pc1vfm64gcexn
7 Mar 19
Business combination disclosure
7:31am
8-K
EX-99.1
bbsmexhc
11 Dec 09
GTx Announces Reduction in Force
12:00am
PRE 14A
n0aamn29k1svfl9p8
8 Mar 11
Preliminary proxy
12:00am
DEF 14A
8wnar078q20dd5x
28 Mar 05
Definitive proxy
12:00am
8-K
dl1 8wgqhc
10 Jun 19
Entry into a Material Definitive Agreement
8:05am